… ProQR Announces Japanese Axiomer™ Patent Upheld Following … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922 , which is related to the …
… ProQR Therapeutics Announces $8.1 Million in New Funding from … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … who have the R270X mutation in MECP2 gene, and is based on ProQR’s proprietary Axiomer RNA editing platform. Axiomer can …
… ProQR Announces Positive Top-Line Results from a Phase 1b … improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a … said Noreen R. Henig, M.D, Chief Medical Officer at ProQR. “I want to thank the entire CF community including …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …
… ProQR Announces First Patients Dosed in Phase 2/3 Pivotal … & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … testing,” said Aniz Girach, M.D., Chief Medical Officer of ProQR. “In a previous clinical study, QR-421a appeared to be …
… ProQR Announces Presentations at ECFS on Eluforsen for … LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … CFF Research Conference. Presentation at ECFS Conference ProQR will deliver a short talk (ePoster) and a poster …
… ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial … and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research & Development of ProQR, said, “QR-1123 aims to block expression of the toxic …